A part of MilliporeSigma

OP95 | Anti-BRCA2 (Ab-1) Mouse mAb (2B)

OP95
Price could not be retrieved
Minimum Quantity needs to be mulitiple of
Upon Order Completion More Information
You Saved ()
 
Request Pricing
Limited AvailabilityLimited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      View Pricing & Availability
      Click To Print This Page

      Overview

      Replacement Information

      Key Specifications Table

      Species ReactivityHostAntibody Type
      H M Monoclonal Antibody

      Pricing & Availability

      Catalog NumberAvailability Packaging Qty/Pack Price Quantity
      OP95-100UG
      Retrieving availability...
      Limited AvailabilityLimited Availability
      Stocked 
      Discontinued
      Limited Quantities Available
      Available
        Remaining : Will advise
          Remaining : Will advise
          Will advise
          Contact Customer Service

          Glass bottle 100 μg
          Retrieving price...
          Price could not be retrieved
          Minimum Quantity needs to be mulitiple of
          Upon Order Completion More Information
          You Saved ()
           
          Request Pricing
          Description
          OverviewRecognzies the ~460 kDa BRCA2 protein in cells expressing a wild type BRCA2 gene. Sold under license of U.S. Patent 5,753,441 and 6,162,897.
          Catalogue NumberOP95
          Brand Family Calbiochem®
          SynonymsAnti-Breast Cancer Susceptibility Protein
          References
          ReferencesAndres, J.L., et al. 1998. Oncogene 16, 2229.
          Chen, J., et al. 1998. Mol. Cell 2, 317.
          Chen, P.L., et al. 1998. Proc. Natl. Acad. Sci. USA 95, 5287.
          Marmorstein, L.Y., et al. 1998. Proc. Natl. Acad. Sci. USA 95, 13869.
          Connor, F., et al. 1997. Nat. Genet. 17, 423.
          Sharan, S.K., et al. 1997. Nature 386, 804.
          Ludwig, T., et al. 1997. Genes Dev. 11, 1226.
          Mizuta, R., et al. 1997. Proc. Natl. Acad. Sci. USA 94, 6927.
          Rajan, J.V., et al. 1997. Dev. Biol. 184, 385.
          Suzuki, A., et al. 1997. Genes Dev. 11, 1242.
          Wong, A.K.C., et al. 1997. J. Biol. Chem. 272, 31941.
          Cannon-Albright, L.A. and M.H. Skolnick. 1996. Semin. Oncol. 23, 1.
          Goggins, M., et al. 1996. Cancer Res. 56, 5360.
          Stratton, M.R. 1996. Hum. Mol. Genet. 5, 1515.
          Tavtigian, S.V., et al. 1996. Nat. Genet. 12, 333.
          Rajan, J.V., et al. 1996. Proc. Natl. Acad. Sci. USA 93, 13078.
          Spillman, M.A. and A.M. Bowcock. 1996. Oncogene 13, 1639.
          Vaughn, J.P., et al. 1996. Cancer Res. 56, 4590.
          Wooster, R., et al. 1995. Nature 378, 789.
          Product Information
          DeclarationSold under license of U.S. Patents 5,837,492 and 6,124,104.
          FormLiquid
          FormulationIn PBS.
          Positive controlMCF7 cells
          Preservative≤0.1% sodium azide
          Applications
          Key Applications Immunoblotting (Western Blotting)
          Immunoprecipitation
          Application NotesImmunoblotting (2 µg/ml)
          Immunoprecipitation (2 µg)
          Application CommentsThe CAPAN-1 cell line, which has 6174delT mutation in the single BRCA2 allele, expresses a truncated BRCA2 protein of 230 kDa that contains the Anti-BRCA2 epitope and retains RAD51 binding but has lost p53 binding. Full length BRCA2 protein will co-migrate on SDS-PAGE with the catalytic subunit of DNA PK which can be detected using Anti-DNA PK, Cat. No. PC127. Antibody should be titrated for optimal results in individual systems.
          Biological Information
          Immunogena recombinant protein consisting of amino acids 1651-1821 of human BRCA2 fused to GST
          ImmunogenHuman
          Clone2B
          HostMouse
          IsotypeIgG2b
          Species Reactivity
          • Human
          Antibody TypeMonoclonal Antibody
          Concentration Label Please refer to vial label for lot-specific concentration
          Physicochemical Information
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Dry Ice Only
          Toxicity Standard Handling
          Storage -20°C
          Do not freeze Ok to freeze
          Special InstructionsFollowing initial thaw, aliquot and freeze (-20°C).
          Packaging Information
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          SDS

          Title

          Safety Data Sheet (SDS) 

          Certificates of Analysis

          TitleLot Number
          OP95

          References

          Reference overview
          Andres, J.L., et al. 1998. Oncogene 16, 2229.
          Chen, J., et al. 1998. Mol. Cell 2, 317.
          Chen, P.L., et al. 1998. Proc. Natl. Acad. Sci. USA 95, 5287.
          Marmorstein, L.Y., et al. 1998. Proc. Natl. Acad. Sci. USA 95, 13869.
          Connor, F., et al. 1997. Nat. Genet. 17, 423.
          Sharan, S.K., et al. 1997. Nature 386, 804.
          Ludwig, T., et al. 1997. Genes Dev. 11, 1226.
          Mizuta, R., et al. 1997. Proc. Natl. Acad. Sci. USA 94, 6927.
          Rajan, J.V., et al. 1997. Dev. Biol. 184, 385.
          Suzuki, A., et al. 1997. Genes Dev. 11, 1242.
          Wong, A.K.C., et al. 1997. J. Biol. Chem. 272, 31941.
          Cannon-Albright, L.A. and M.H. Skolnick. 1996. Semin. Oncol. 23, 1.
          Goggins, M., et al. 1996. Cancer Res. 56, 5360.
          Stratton, M.R. 1996. Hum. Mol. Genet. 5, 1515.
          Tavtigian, S.V., et al. 1996. Nat. Genet. 12, 333.
          Rajan, J.V., et al. 1996. Proc. Natl. Acad. Sci. USA 93, 13078.
          Spillman, M.A. and A.M. Bowcock. 1996. Oncogene 13, 1639.
          Vaughn, J.P., et al. 1996. Cancer Res. 56, 4590.
          Wooster, R., et al. 1995. Nature 378, 789.

          Brochure

          Title
          DNA Repair Pathway Poster
          Data Sheet

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision12-November-2008 JSW
          SynonymsAnti-Breast Cancer Susceptibility Protein
          ApplicationImmunoblotting (2 µg/ml)
          Immunoprecipitation (2 µg)
          DescriptionPurified mouse monoclonal antibody generated by immunizing mice with the specified immunogen and fusing splenocytes with myeloma cells. Recognizes the ~460 kDa BRCA2 protein.
          BackgroundInherited mutations in the BRCA2 gene enhances the risk of familial breast cancer with the neoplasia related to loss of the wild type allele. Human BRCA2 encodes a 3418 amino acid protein with little homology to any known proteins. Transcription of BRCA2 appears to be co-ordinately regulated with BRCA1 during proliferation and differentiation with low level expression in early G1 and maximal expression occurring during the G1/S transition of the cell cycle. While loss of BRCA2 is associated with early onset breast cancer, the gene is also critical for embryogenesis. Although some mice nullizygous for BRCA2 die during embryogenesis, there have been BRCA2 knock-out mice that do survive to adulthood, albeit with various defects particularly in DNA repair capability. Loss of BRCA2 expression in embryogenesis does not appear to affect apoptosis, per se, but proliferation is impaired, perhaps due to enhanced expression of p21WAF1. Although the precise role for BRCA2 is still to be determined, recent studies implicate BRCA2 in DNA repair and recombination processes due to association with p53 and Rad51 and co-localization with BRCA1. BRCA2 levels, as well as BRCA1 levels, decline following DNA damage and the decrease in BRCA2 accompanies activation of p53. Interestingly, BRCA2 appears capable of specifically inhibiting p53 transcriptional activity, which implicates BRCA2 as a mediator of cell cycle control and DNA repair.
          HostMouse
          Immunogen speciesHuman
          Immunogena recombinant protein consisting of amino acids 1651-1821 of human BRCA2 fused to GST
          Clone2B
          IsotypeIgG2b
          Specieshuman
          Positive controlMCF7 cells
          FormLiquid
          FormulationIn PBS.
          Concentration Label Please refer to vial label for lot-specific concentration
          Preservative≤0.1% sodium azide
          CommentsThe CAPAN-1 cell line, which has 6174delT mutation in the single BRCA2 allele, expresses a truncated BRCA2 protein of 230 kDa that contains the Anti-BRCA2 epitope and retains RAD51 binding but has lost p53 binding. Full length BRCA2 protein will co-migrate on SDS-PAGE with the catalytic subunit of DNA PK which can be detected using Anti-DNA PK, Cat. No. PC127. Antibody should be titrated for optimal results in individual systems.
          Storage -20°C
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing initial thaw, aliquot and freeze (-20°C).
          Toxicity Standard Handling
          ReferencesAndres, J.L., et al. 1998. Oncogene 16, 2229.
          Chen, J., et al. 1998. Mol. Cell 2, 317.
          Chen, P.L., et al. 1998. Proc. Natl. Acad. Sci. USA 95, 5287.
          Marmorstein, L.Y., et al. 1998. Proc. Natl. Acad. Sci. USA 95, 13869.
          Connor, F., et al. 1997. Nat. Genet. 17, 423.
          Sharan, S.K., et al. 1997. Nature 386, 804.
          Ludwig, T., et al. 1997. Genes Dev. 11, 1226.
          Mizuta, R., et al. 1997. Proc. Natl. Acad. Sci. USA 94, 6927.
          Rajan, J.V., et al. 1997. Dev. Biol. 184, 385.
          Suzuki, A., et al. 1997. Genes Dev. 11, 1242.
          Wong, A.K.C., et al. 1997. J. Biol. Chem. 272, 31941.
          Cannon-Albright, L.A. and M.H. Skolnick. 1996. Semin. Oncol. 23, 1.
          Goggins, M., et al. 1996. Cancer Res. 56, 5360.
          Stratton, M.R. 1996. Hum. Mol. Genet. 5, 1515.
          Tavtigian, S.V., et al. 1996. Nat. Genet. 12, 333.
          Rajan, J.V., et al. 1996. Proc. Natl. Acad. Sci. USA 93, 13078.
          Spillman, M.A. and A.M. Bowcock. 1996. Oncogene 13, 1639.
          Vaughn, J.P., et al. 1996. Cancer Res. 56, 4590.
          Wooster, R., et al. 1995. Nature 378, 789.